A kind of compatibility method of dimethylaminobutyrate dilinoleyl methyl ester
Through the dimethylbutyrate diolefin methyl ester compatibility method, a compatibility cascade system and taboo database were established, and combined with decision-making models and biological evolution modules, the problems of component proportion control and compatibility taboos in the existing technology were solved, achieving rapid and accurate results The compatibility strategy is determined and the compatibility effect is improved.
Patent Information
- Application Number
- CN202411224984.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-09-03
AI Technical Summary
Existing drug compatibility technologies are difficult to accurately control component ratios and interactions, and cannot guarantee the best compatibility strategy, and fail to fully consider compatibility taboos, which poses safety risks.
Use dimethylbutyrate diolefinite methyl ester as the compatibility body to establish a compatibility cascade system, introduce a compatibility taboo database, supervise and train the compatibility decision model, perform hierarchical analysis and bioevolution module verification, determine effective compatibility strategies and conduct terminals Visual display.
It has achieved rapid and accurate determination of the best compatibility strategy, fully considering compatibility taboos, improving the accuracy and safety of compatibility, and ensuring the ideal compatibility effect.
Smart Images

Figure CN118737311B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of data processing, and in particular to a method for preparing dilinoleyl methyl dimethylaminobutyrate. Background Art
[0002] With the rapid development of the biopharmaceutical field, the demand for highly efficient and low-toxic cationic lipids is increasing. In the process of drug development and pharmaceutical manufacturing, the application of intelligent technology is becoming more and more extensive. As an emerging technical means, intelligent compatibility can improve the efficiency and accuracy of compatibility and reduce operating costs, so it has received widespread attention.
[0003] At present, the existing drug compatibility technology mainly relies on experience and trial and error methods, lacking scientific and systematic analysis methods. At the same time, in the process of compatibility, compatibility contraindications are often not fully considered, posing potential safety risks. In addition, the existing compatibility methods fail to conduct a comprehensive hierarchical analysis of drug delivery systems and delivery elements, resulting in unsatisfactory compatibility effects.
[0004] In summary, the existing technology cannot guarantee the best compatibility strategy because it is difficult to accurately control the proportions and interactions of various ingredients. Summary of the invention
[0005] The purpose of the present application is to provide a method for preparing dimethylaminobutyrate dilinoleyl methyl ester, so as to solve the problem that the prior art cannot guarantee the best preparation strategy due to the difficulty in accurately controlling the proportion and interaction of various components.
[0006] In view of the above problems, the present application provides a method for preparing dilinoleyl methyl dimethylaminobutyrate.
[0007] The present application provides a compatibility method for dimethylaminobutyrate, wherein the method comprises: taking dimethylaminobutyrate as a compatibility subject, establishing a compatibility cascade system; introducing a compatibility taboo library, combining the compatibility cascade system, supervising the training of a compatibility decision model, wherein the compatibility decision model comprises a compatibility decision branch and a taboo decision branch, wherein the compatibility decision branch comprises a first compatibility block and a second optimization block, and lateral interaction channels are established with the taboo decision branch respectively; reading a compatibility task based on the compatibility subject, including compatibility elements and expected responses; combining the compatibility decision model, performing a hierarchical compatibility analysis on the compatibility task, fitting the hierarchical analysis results to determine a target compatibility strategy, wherein the hierarchical compatibility comprises a delivery system compatibility and a delivery element compatibility; combining a biological evolution module, performing a verification and compensation analysis on the target compatibility strategy, determining an effective compatibility result and performing a terminal visualization display.
[0008] One or more technical solutions provided in this application have at least the following technical effects or advantages:
[0009] A compatibility cascade system is established by taking dilinoleyl methyl dimethylaminobutyrate as the compatibility subject; a compatibility taboo library is introduced, and a compatibility decision model is supervised and trained in combination with the compatibility cascade system, wherein the compatibility decision model includes a compatibility decision branch and a taboo decision branch, and the compatibility decision branch includes a first compatibility block and a second optimization block, and lateral interaction channels are established with the taboo decision branch respectively; a compatibility task based on the compatibility subject is read, including compatibility elements and expected responses; hierarchical compatibility analysis is performed on the compatibility task in combination with the compatibility decision model, and the hierarchical analysis results are fitted to determine the target compatibility strategy, wherein the hierarchical compatibility includes the delivery system compatibility and the delivery element compatibility; in combination with the biological evolution module, the target compatibility strategy is verified and compensated, and the effective compatibility results are determined and displayed visually on the terminal, which effectively solves the problem that the prior art cannot guarantee the best compatibility strategy due to the difficulty in accurately controlling the proportions and interactions of various components, and can fully consider the compatibility taboos, conduct a comprehensive hierarchical analysis, and quickly and accurately determine the best compatibility strategy.
[0010] The above description is only an overview of the technical solution of the present application. In order to more clearly understand the technical means of the present application, it can be implemented according to the contents of the specification, and in order to make the above and other purposes, features and advantages of the present application more obvious and easy to understand, the specific implementation methods of the present application are specifically cited below. It should be understood that the content described in this section is not intended to identify the key or important features of the embodiments of the present application, nor is it intended to limit the scope of the present application. Other features of the present application will become easy to understand through the following description. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] In order to more clearly illustrate the technical solutions in the present application or the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying any creative work.
[0012] Figure 1 This is a schematic diagram of a process for preparing dimethylaminobutyrate;
[0013] Figure 2 This is a schematic diagram of a process for determining a target compatibility strategy in a dimethylaminobutyrate dilinoleate compatibility method of the present application. DETAILED DESCRIPTION
[0014] The present application provides a method for formulating dimethylaminobutyrate, which solves the problem that the prior art cannot guarantee the best formulating strategy due to the difficulty in accurately controlling the proportions and interactions of various components. The present application can fully consider the incompatibility taboos, conduct a comprehensive hierarchical analysis, and quickly and accurately determine the best formulating strategy.
[0015] Below, the technical solutions in the present application will be clearly and completely described with reference to the accompanying drawings. Obviously, the described embodiments are only part of the embodiments of the present application, rather than all of the embodiments of the present application. It should be understood that the present application is not limited to the example embodiments described herein. Based on the embodiments of the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present application. It should also be noted that, for the convenience of description, only the parts related to the present application are shown in the accompanying drawings, rather than all of them.
[0016] Embodiment 1
[0017] Please see attached Figure 1 The present application provides a method for preparing dimethylaminobutyrate, wherein the method specifically comprises the following steps:
[0018] S1: Using dimethylaminobutyrate as the main component, a compatibility cascade system is established.
[0019] Specifically, dimethylaminobutyrate is used as the main compatibility agent, and its unique pH-dependent charge-variable property is used to deliver drugs or nutrients, being positively charged under acidic conditions and electrically neutral under physiological pH conditions. Auxiliary ingredients with good compatibility with dimethylaminobutyrate are selected, and these ingredients do not produce adverse chemical reactions with the main body. Primary compatibility determines the basic ingredients that are directly compatible with dimethylaminobutyrate, such as solvents, stabilizers, etc., such as PEG polyethylene glycol or glycerol. Secondary compatibility, on the basis of primary compatibility, adds auxiliary ingredients that enhance the efficacy or delivery efficiency, such as penetration enhancers, targeting ligands, etc. Tertiary compatibility is targeted at specific applications, such as oral medications, injections, or skin administration. For example, some ingredients that protect the gastric mucosa, such as mannitol or starch, can be added to reduce gastric irritation, and the compatibility scheme can be further fine-tuned to meet the needs of different routes of administration.
[0020] S2: Introduce a compatibility taboo library, combine it with the compatibility cascade system, and supervise the training of a compatibility decision model. The compatibility decision model includes a compatibility decision branch and a taboo decision branch. The compatibility decision branch includes a first compatibility block and a second optimization block, and lateral interaction channels are established with the taboo decision branch respectively.
[0021] Specifically, the first compatibility block is mainly responsible for the generation of preliminary compatibility schemes. Based on the principles and methods of the compatibility cascade system, it selects ingredients that are compatible with dimethylaminobutyrate and forms a preliminary compatibility scheme. The second optimization block is responsible for optimizing and adjusting the scheme. It will refine and improve the preliminary scheme based on the information in the compatibility taboo library and the suggestions fed back from the taboo decision branch. The taboo decision branch uses the data in the compatibility taboo library to supervise and evaluate the schemes proposed by the compatibility decision branch. It checks whether there are any compatibility taboos in the scheme or the potential risks that may be caused by certain combinations of ingredients. The compatibility decision branch and the taboo decision branch exchange information through the lateral interaction channel. When the compatibility decision branch proposes a preliminary scheme, the taboo decision branch will evaluate it and provide feedback through the interaction channel. This interactive method allows the model to consider compatibility taboos and potential risks in real time when generating a compatibility scheme, thereby improving the accuracy and safety of the compatibility.
[0022] S3: Read the compatibility task based on the compatibility subject, including compatibility elements and expected responses.
[0023] Specifically, compatibility factors are key information such as various ingredients, proportions, conditions, etc. that need to be considered in the compatibility process. Including core ingredients, concentration, purity and quality. Auxiliary ingredients, such as solvents, stabilizers, penetration enhancers, etc., the types, concentrations and mechanisms of action of these ingredients. Environmental conditions, such as temperature, pH value, ionic strength, etc., these conditions may affect the stability and effect of the compatibility. The expected response refers to the effect or goal that the system should achieve after the compatibility is completed. Including stability, the stability requirements of the compatibility system under specified conditions. Solubility is the degree of solubility in water or other solvents. Bioavailability, the amount and rate of drug absorption into the systemic circulation. Obtain a detailed description of the compatibility task from the user or database. Extract key compatibility elements from the task description, such as ingredient list, proportion relationship, environmental conditions, etc. Determine the effect indicators and standards that should be achieved after the compatibility is completed.
[0024] S4: In combination with the compatibility decision model, a hierarchical compatibility analysis is performed on the compatibility task, and the hierarchical analysis results are fitted to determine the target compatibility strategy, wherein the hierarchical compatibility includes delivery system compatibility and delivery element compatibility.
[0025] Specifically, according to the compatibility cascade system, select compatible auxiliary ingredients, such as solvents, stabilizers, etc. Evaluate the stability of the entire delivery system under predetermined conditions, including the influence of environmental factors such as temperature and pH value. Fit the results of the hierarchical compatibility analysis to determine the optimal ratio and combination of the components through statistical methods. Based on the fitting results, determine the final compatibility strategy, including the types, concentrations and proportions of various components. This strategy should meet the expected requirements of stability, solubility, bioavailability and efficacy.
[0026] S5: Combined with the biological evolution module, the target compatibility strategy is verified and compensated, and the effective compatibility result is determined and displayed visually on the terminal.
[0027] Specifically, the biological evolution module can be used to simulate and predict the behavior and effect of the compatibility components in the organism, so as to verify the target compatibility strategy. This includes simulation analysis of drug metabolism dynamics and pharmacodynamics. By simulating the absorption, distribution, metabolism and excretion process of the drug in the body, the concentration change and time curve of the drug are predicted to verify the rationality of the compatibility strategy. The interaction between the drug and the target is analyzed, and the therapeutic effect and possible side effects of the drug on the organism are predicted to evaluate the effectiveness of the compatibility strategy. Compensation analysis is to adjust the compatibility strategy to cope with possible deviations or deficiencies. This includes identifying possible risk points in the compatibility strategy through the simulation of the biological evolution module, such as low bioavailability or adverse reactions of certain components. According to the identification results of the risk points, the proportion of each component is adjusted to improve the efficacy and reduce side effects. The terminal visualization interface is constructed using visual programming tools or data visualization frameworks. All components and their proportions included in the compatibility strategy are displayed. The concentration change and time curve of the drug in the body, as well as the predicted therapeutic effect, are displayed in charts.
[0028] Furthermore, step S1 of the present application also includes:
[0029] For the compatibility subject, a big data homology search is performed to determine the subject compatibility record, including compatibility data and biological response data; the subject compatibility record is traversed to extract the synergistic relationship based on the delivery system and the compatibility relationship based on the delivery element, and a plurality of compatibility pairs are determined by fitting; the plurality of compatibility pairs are traversed to identify the matching degree and determine the unit gain relationship, which is the functional gain step under the unit ratio; the plurality of identified compatibility pairs are subjected to progressive hierarchical cascade integration of correlation to determine the compatibility cascade system.
[0030] Specifically, using big data technology and tools, we conducted extensive searches in various databases, literature, and scientific research materials, with the goal of finding all compatibility data and biological response data related to dilinoleyl methyl dimethylaminobutyrate. This includes previous experimental records, published research papers, patent applications, etc. Among the large amount of data collected, we screened out records with dilinoleyl methyl dimethylaminobutyrate as the compatibility subject. Then, we conducted a detailed analysis of these records, especially focusing on the synergistic relationship and compatibility relationship between the delivery system and the delivery elements. We analyzed how the components in the delivery system work synergistically with dilinoleyl methyl dimethylaminobutyrate to improve the stability and delivery efficiency of the drug. For example, some components may help protect dilinoleyl methyl dimethylaminobutyrate from degradation or enhance its ability to penetrate cell membranes. We extracted the compatibility relationship between delivery elements, such as drugs, penetration enhancers, and dilinoleyl methyl dimethylaminobutyrate. Based on the extracted synergistic relationship and compatibility relationship, we determined multiple possible compatibility pairs through data fitting and analysis. Each compatibility pair represents a specific combination of components and proportions, which are expected to improve the overall performance of the drug. Evaluate the matching degree of each compatibility pair. Use computational models to predict the performance of each compatibility pair. Compatibility pairs with high matching degrees are more likely to perform well in practical applications. Analyze the impact of unit ratio changes in the components of each compatibility pair on the overall performance. Finally, perform progressive hierarchical cascade integration.
[0031] Furthermore, the present application also includes: the delivery system is a delivery material including dilinoleyl methyl dimethylaminobutyrate, and the delivery element is a biologically functional reactant based on the compatibility task.
[0032] Specifically, the delivery elements are mainly based on the biofunctional reactants of the compatibility task, which are used in combination with dimethoate to enhance the therapeutic effect of the drug or achieve specific biological functions. They include therapeutic drug molecules, penetration enhancers, stabilizers, etc., which work synergistically with dimethoate to form an efficient delivery system.
[0033] Further, if Figure 2 As shown, step S4 of the present application also includes:
[0034] Based on the compatibility task, determine the element compatibility task and the system compatibility task; based on the element compatibility task, perform a first-level compatibility analysis based on the compatibility decision model to determine the element compatibility strategy and store it; based on the system compatibility task, perform a second-level compatibility analysis based on the compatibility decision model to determine the system compatibility strategy; perform compatibility analysis and homologous substitution fitting on the element compatibility strategy and the system compatibility strategy to determine the target compatibility strategy.
[0035] Specifically, the element compatibility task includes the compatibility relationship between delivery elements, such as drugs, penetration enhancers, etc. Find the best combination and ratio between these elements to improve the bioavailability and therapeutic effect of the drug. The system compatibility task includes the compatibility of the core ingredient dimethylaminobutyrate with other auxiliary ingredients. Based on the element compatibility task and the compatibility decision model, a first-level compatibility analysis is performed. Including analyzing the interaction and influence between different delivery elements. Determine the element compatibility strategy, that is, the best combination and ratio of each delivery element through data fitting and model prediction. Based on the system compatibility task and the compatibility decision model, a second-level compatibility analysis is performed. Determine the system compatibility strategy through model analysis and data fitting. Perform compatibility analysis on the determined element compatibility strategy and system compatibility strategy. Check whether there is a conflict or inconsistency between the two. If incompatibility is found, perform homologous replacement fitting. That is, adjust or replace certain ingredients without changing the overall compatibility effect to achieve compatibility between the two. The final target compatibility strategy should meet the requirements of both element compatibility and system compatibility. For example, the delivery system of a certain compatibility element is not compatible with dimethylaminobutyrate, that is, the delivery system. We conduct an interchangeability analysis on the delivery system or the delivery element, perform homologous substitution and equivalent matching, and finally fit the two strategies.
[0036] Furthermore, the present application also includes:
[0037] Based on the first compatibility block, the elements are matched with the organism of the element matching task as the guide to determine the first element matching strategy; in combination with the lateral interaction channel, based on the taboo decision branch, the first element matching strategy is subjected to taboo matching verification and adjustment, and then transferred to the second optimization block; with functional gain as the optimization target and matching elements and ratios as the optimization benchmark, multi-objective optimization is performed to determine the matching strategy, and the functional gain at least includes biological stability, targeting and cellular internalization efficiency.
[0038] Specifically, in the first compatibility block, the biological orientation of the element compatibility task is taken as the basis, that is, considering how the delivery elements, such as drugs, penetration enhancers, etc., can better interact with the organism to improve the bioavailability and therapeutic effect of the drug. By analyzing the interactions between different delivery elements and their compatibility with the organism, it is determined which elements can be combined to produce the best therapeutic effect. After completing the element compatibility analysis, a preliminary element compatibility strategy will be formed. The lateral interaction channel represents the path of mutual influence or information exchange between different compatibility elements. In the compatibility process, consider how these channels affect the compatibility relationship between elements. The taboo decision branch contains some known adverse compatibility relationships or compatibility combinations that need to be avoided. The information in the taboo decision branch is used to verify the first element compatibility strategy. If a taboo compatibility relationship is found, the strategy needs to be adjusted to avoid potential risks or adverse effects. In the optimization process, the functional gain is the goal, that is, to seek those compatibility elements and ratios that can significantly improve drug performance, such as biological stability, targeting, and cellular internalization efficiency. In the optimization process, not only which elements should be included, but also their proportions should be considered. By adjusting the types and proportions of elements, the best therapeutic effect is sought. After completing the multi-objective optimization, a final element matching strategy will be determined. This strategy can maximize the therapeutic effect while ensuring the safety of the drug.
[0039] Furthermore, the present application also includes:
[0040] Finite element analysis is used as an iterative optimization method, and optimization rules are iteration in the superior direction and retreat in the inferior direction, and each gain target has a priority mark; based on the optimization benchmark, any number of optimization targets are randomly determined, and the optimization method is the intersection of random perturbations in the optimization space and the strategy points of the better strategy, and iterative optimization is performed to select the global optimal strategy as the matching strategy.
[0041] Specifically, finite element analysis is used as an iterative optimization method to optimize the combination scheme by simulating and analyzing the effects of different combination strategies. Iteration in the direction of superiority and retreat in the direction of inferiority are used as optimization rules. If the new strategy is better than the current strategy, continue to explore in this direction; if the new strategy is inferior to the current strategy, return to the previous superior strategy. Each gain target, such as biological stability, targeting, and cell internalization efficiency, is assigned a different priority label. This helps to weigh and select according to the importance of the target during the optimization process. Based on the optimization benchmark, the combination elements and the ratio, a certain number of optimization targets are randomly selected. The spatial range of optimization, that is, the possible range of variation of the combination elements and the ratio, is determined. In the optimization space, a new combination strategy is generated by randomly perturbing the current strategy or crossing the strategy points with other superior strategies. Finite element analysis is performed on the newly generated combination strategy to evaluate its performance on each gain target. According to the evaluation results and the priority of the gain target, the strategy with better performance is selected as the starting point of the next iteration. The conditions for the termination of the iteration are set, such as reaching the preset number of iterations, the improvement of the strategy performance is less than the preset threshold, etc. After multiple iterations, the best performing strategy is selected as the global optimal strategy, which is the desired combination strategy.
[0042] Furthermore, step S5 of the present application also includes:
[0043] The target compatibility strategy is read to determine whether it is a new compatibility type; if it is a new compatibility type, a derivation verification instruction is generated and responded to the biological evolution module; based on the compatibility task, a scenario simulation is performed on the biological evolution module, and the evolutionary derivation of the target compatibility strategy is executed to determine the verification data; based on the verification data, a compensation analysis is performed on the target compatibility strategy.
[0044] Specifically, the determined target compatibility strategy is read to determine whether the compatibility strategy belongs to a new compatibility category. If it is a verified category, a complete verification process is required; if it is a new compatibility category, further verification is required. If it is determined that the target compatibility strategy belongs to a new compatibility category, a derivation verification instruction is generated, which will trigger the verification process. The verification instruction will be sent to the biological evolution module, which is a system that can simulate biological environment and drug action. In the biological evolution module, a simulation scenario is created according to the specific requirements of the compatibility task, such as a specific biological environment, drug action mechanism, etc. In this simulation scenario, the system will execute the target compatibility strategy, observe and record its evolution process and results. Including drug release, distribution, metabolism, and interaction with organisms. Through simulation and evolutionary derivation, a series of data on the performance of the compatibility strategy are collected. The collected verification data is deeply analyzed to evaluate the actual effect of the target compatibility strategy. If it is found that the compatibility strategy is insufficient in some aspects or needs to be optimized, a compensation analysis is performed to propose improvement suggestions or adjustment plans. Including adjusting the drug ratio, changing the delivery method, etc.
[0045] Furthermore, the present application also includes:
[0046] If the verification data is qualified, the target compatibility strategy is used as the effective compatibility result; if the verification data is unqualified, abnormal verification data tracing and strategy compensation are performed until the verification is qualified to generate the effective compatibility result.
[0047] Specifically, the verification data collected through the simulation and evolutionary deduction of the biological evolution module are reviewed to determine whether they meet the preset standards or requirements. If the verification data meets all the preset standards, it is considered qualified. Once the verification data is qualified, the target compatibility strategy will be considered valid and determined as a valid compatibility result. If the verification data does not meet the preset standards, it is considered unqualified. In the case of unqualified data, traceability analysis is performed to find out the specific reasons for the unqualified data. This includes inspections of multiple aspects such as the setting of simulation scenarios, the specific implementation of compatibility strategies, and data collection and analysis methods. According to the results of the traceability analysis, the compatibility strategy is adjusted or compensated accordingly. This includes modifying the drug ratio, adjusting the delivery method, optimizing the simulation scenario settings, etc. After strategy compensation, simulation and verification are required again to ensure that the new compatibility strategy can meet all preset standards. This process may be repeated until a compatibility strategy with qualified verification data is found. Once a compatibility strategy with qualified verification data is found, the strategy will be considered a valid compatibility result.
[0048] The above description of the disclosed embodiments enables those skilled in the art to implement or use the present application. Various modifications to these embodiments will be apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present application. Therefore, the present application will not be limited to the embodiments shown herein, but will conform to the widest scope consistent with the principles and novel features disclosed herein.
[0049] Obviously, those skilled in the art can make various changes and modifications to the present application without departing from the spirit and scope of the present application. Thus, if these modifications and variations of the present application belong to the scope of the present application and its equivalent technology, the present application is also intended to include these modifications and variations.
Claims
1. A method for preparing dilinoleyl methyl dimethylaminobutyrate, It is characterized in that The method comprises: With dimethylaminobutyrate as the main component, a compatibility cascade system was established; Introducing a compatibility taboo library, combining the compatibility cascade system, and supervising the training of a compatibility decision model, wherein the compatibility decision model includes a compatibility decision branch and a taboo decision branch, wherein the compatibility decision branch includes a first compatibility block and a second optimization block, and each of the blocks has a lateral interaction channel established with the taboo decision branch; Reading a compatibility task based on the compatibility subject, including compatibility elements and expected responses; Combined with the compatibility decision model, a hierarchical compatibility analysis is performed on the compatibility task, and the hierarchical analysis results are fitted to determine the target compatibility strategy, wherein the hierarchical compatibility includes delivery system compatibility and delivery element compatibility; Combined with the biological evolution module, the target compatibility strategy is verified and compensated, and the effective compatibility results are determined and displayed visually on the terminal; The establishment of the compatibility cascade system comprises: For the compatibility subject, a big data homology search is performed to determine the subject compatibility record, including compatibility data and biological response data; Traversing the main compatibility records, extracting the synergistic relationship based on the delivery system and the compatibility relationship based on the delivery elements, and fitting and determining a plurality of compatibility pairs; Traversing the plurality of compatibility pairs, identifying the matching degree and determining a unit gain relationship, wherein the unit gain relationship is a functional gain step under a unit ratio; Performing progressive hierarchical cascade integration of the correlations on the identified multiple compatibility pairs to determine the compatibility cascade system; Combined with the compatibility decision model, a hierarchical compatibility analysis is performed on the compatibility task, including: Based on the matching task, determining the element matching task and the system matching task; Based on the element matching task, a layer of matching analysis is performed based on the matching decision model to determine the element matching strategy and store it; Based on the system compatibility task, a second-level compatibility analysis is performed based on the compatibility decision model to determine the system compatibility strategy; Compatibility analysis and homologous substitution fitting are performed on the element compatibility strategy and the system compatibility strategy to determine the target compatibility strategy.
2. The method according to claim 1, It is characterized in that The delivery system is a delivery material including dilinoleyl methyl dimethylaminobutyrate, and the delivery element is a reactant with biological functionality based on the compatibility task.
3. The method according to claim 1, It is characterized in that A compatibility analysis is performed based on the compatibility decision model, including: Based on the first compatibility block, taking the organism of the element compatibility task as a guide, performing element compatibility and determining a first element compatibility strategy; In combination with the lateral interaction channel, based on the taboo decision branch, the first factor matching strategy is checked and adjusted for taboo matching, and transferred to the second optimization block; Taking function gain as the optimization target, and taking compatibility elements and ratios as the optimization benchmark, multi-objective optimization is performed to determine the compatibility strategy, wherein the function gain at least includes biological stability, targeting and cellular internalization efficiency.
4. The method according to claim 3, It is characterized in that The multi-objective optimization process comprises: Finite element analysis is used as an iterative optimization method, with optimal iteration and inferior retreat as optimization rules, and each gain target has a priority mark; Based on the optimization benchmark, any number of optimization objectives are randomly determined, and the random perturbation in the optimization space and the intersection of the strategy points of the better strategy are used as the optimization method to perform iterative optimization and select the global optimal strategy as the matching strategy.
5. The method according to claim 1, It is characterized in that The combined biological evolution module verifies and compensates the target compatibility strategy, including: Read the target compatibility strategy to determine whether it is a new compatibility type; If it is a new compatibility class, a derivation verification instruction is generated and responded to the biological evolution module; Based on the compatibility task, the biological evolution module is subjected to scenario simulation, the evolutionary derivation of the target compatibility strategy is executed, and verification data is determined; Based on the verification data, a compensation analysis is performed on the target compatibility strategy.
6. The method according to claim 5, It is characterized in that Based on the verification data, a compensation analysis is performed on the target compatibility strategy, including: If the verification data is qualified, the target compatibility strategy is used as the effective compatibility result; If the verification data fails, the abnormal verification data is traced and strategy compensation is performed until the verification passes, thereby generating the effective compatibility result.
